The tumor microenvironment (TME) has been reported to crucially regulate tumor growth, progression, migration, and angiogenesis in different cancer types including brain tumors. TME is a complex network of cancer cells, stromal cells and, most importantly, tumor infiltrating immune cells (TIICs). TIICs including Th2 cells, cancer-associated fibroblasts (CAFs), regulatory T cells (Tregs), M2 macrophages, and myeloid-derived suppressor cells (MDSCs) not only regulate the immunosurveillance and survival of cancer but also accelerate tumor progression by creating a permissive microenvironment that stimulates tumor growth. Accumulating evidence has demonstrated that alterations in the number of TIICs in the TME have been shown to affect clinical outcomes and immunotherapy in various malignant tumor types. Immunotherapy, represented by immune checkpoint blockade, has become promising in revolutionizing cancer treatment. However, no clinical trial about immunotherapy in brain tumors has demonstrated survival benefits.
TIICs have already been successfully extracted from brain tumors, providing convincing evidence of the existence of abundant TIICs in the brain tumor microenvironment. The critical role of several TIICs in brain tumors have also been reported. Moreover, research about TIICs may also inspire the exploration of novel tumor therapy options. Therefore, it is important to characterize the TME landscape, especially the TIICs in brain tumors, and explore the potential factors impacting immunotherapy.
This Research Topic aims to deepen our understanding of the interaction among the TIICs in TME of brain tumors, and the potential prognostic factors in TME for predicting patients' survival, and the impact of specific components from TME on immunotherapy or other tumor therapy efficacy.
We, therefore, welcome the submission of Original Research Articles, Reviews, and Expert Opinions on themes including, but not limited to:
1. Exploring the crosstalk between TIICs and brain tumor cells
2. Identifying novel prognostic models based on TME of brain tumors
3. Influence of TIICs on the survival of brain tumors
4. Immunotherapy targeting brain tumors
5. Delineating the landscape of TIICs in brain tumors at single-cell sequencing level
6. The association between TIICs and glioma sensitivity to tumor therapy
7. The clinical research of brain tumor immunotherapy
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted.
The tumor microenvironment (TME) has been reported to crucially regulate tumor growth, progression, migration, and angiogenesis in different cancer types including brain tumors. TME is a complex network of cancer cells, stromal cells and, most importantly, tumor infiltrating immune cells (TIICs). TIICs including Th2 cells, cancer-associated fibroblasts (CAFs), regulatory T cells (Tregs), M2 macrophages, and myeloid-derived suppressor cells (MDSCs) not only regulate the immunosurveillance and survival of cancer but also accelerate tumor progression by creating a permissive microenvironment that stimulates tumor growth. Accumulating evidence has demonstrated that alterations in the number of TIICs in the TME have been shown to affect clinical outcomes and immunotherapy in various malignant tumor types. Immunotherapy, represented by immune checkpoint blockade, has become promising in revolutionizing cancer treatment. However, no clinical trial about immunotherapy in brain tumors has demonstrated survival benefits.
TIICs have already been successfully extracted from brain tumors, providing convincing evidence of the existence of abundant TIICs in the brain tumor microenvironment. The critical role of several TIICs in brain tumors have also been reported. Moreover, research about TIICs may also inspire the exploration of novel tumor therapy options. Therefore, it is important to characterize the TME landscape, especially the TIICs in brain tumors, and explore the potential factors impacting immunotherapy.
This Research Topic aims to deepen our understanding of the interaction among the TIICs in TME of brain tumors, and the potential prognostic factors in TME for predicting patients' survival, and the impact of specific components from TME on immunotherapy or other tumor therapy efficacy.
We, therefore, welcome the submission of Original Research Articles, Reviews, and Expert Opinions on themes including, but not limited to:
1. Exploring the crosstalk between TIICs and brain tumor cells
2. Identifying novel prognostic models based on TME of brain tumors
3. Influence of TIICs on the survival of brain tumors
4. Immunotherapy targeting brain tumors
5. Delineating the landscape of TIICs in brain tumors at single-cell sequencing level
6. The association between TIICs and glioma sensitivity to tumor therapy
7. The clinical research of brain tumor immunotherapy
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted.